drugset / Trial / NCT06324604

Safety, Pharmacokinetics, and Pharmacodynamics of MTX-101 in Healthy Adults and Patients

NCT06324604 ↗

Phase 1 Recruiting 96 enrolled Mozart Therapeutics Australia Pty Ltd
RandomizedCrossoverTriple-blindBasic science

Summary

First in human study to understand the potential side effects of MTX-101, how long MTX-101 lasts in the human body, and how MTX-101 affects specific human immune cells.

Timeline

Start
2024-06-13
Primary completion
2027-03-31
Completion
2027-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject MTX101 Unknown — Intravenous